Sunshine Biopharma Inc. income statement

In fiscal 2025, Sunshine Biopharma Inc. reported revenue of $36.3m, up 4.1% on the year before, operating income of −$6.2m (a -17.2% margin) and net income of −$6.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sunshine Biopharma Inc.: income statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	0	0	0	0	4	24	35	36	35
Cost of revenue	0	0	0	0	0	3	16	24	24	25
Gross profit	0	0	0	0	0	2	8	11	12	11
Research and development	0	0	0	0	1	1	2	1	1	0
General and administrative	1	1	1	1	3	29	13	16	18	17
Operating income	−1	−1	−1	−1	−2	−27	−5	−6	−6	−6
Interest expense	0	0	0	0	0	0	0	0	0	—
Income before tax	—	—	—	—	−12	−27	−4	−5	−6	−6
Income tax	—	—	—	0	0	0	0	−0	0	0
Net income	−1	−2	−2	−3	−12	−27	−5	−5	−6	−6
Diluted EPS	—	—	—	—	−$9520.00	−$1.76	−$351.36	−$7.32	—	—
Diluted shares (average)	44m	3m	11m	1m	3m	15m	—	—	4m	—
EBITDA	−1	−1	−1	−1	−2	−27	−5	−6	−6	−6

US$ thousands unless shown otherwise. Fiscal quarters.

Sunshine Biopharma Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	8,435	9,595	8,901	9,410	9,417	8,577	8,089	9,264
Cost of revenue	5,569	6,502	6,171	5,987	6,344	5,548	5,908	6,837
Gross profit	2,866	3,093	2,730	3,423	3,074	3,029	2,181	2,427
Research and development	126	149	215	196	119	74	32	13
General and administrative	3,973	5,131	4,026	5,478	4,160	4,819	3,577	4,040
Operating income	−1,106	−2,038	−1,296	−2,055	−1,087	−1,790	−1,396	−1,613
Interest expense	0	9	0	0	0	0	—	—
Income before tax	−983	−2,287	−1,220	−1,980	−1,021	−1,733	−1,244	−1,564
Income tax	215	−129	−40	−209	−137	408	0	0
Net income	−1,198	−2,158	−1,180	−1,771	−884	−2,141	−1,244	−1,564
Diluted EPS	—	$2.10	−$4.40	−$0.82	—	—	—	—
EBITDA	−1,042	−1,972	−1,231	−1,982	−991	−1,691	−1,319	−1,535

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BGM vs SBFM IMCC vs SBFM SBFM vs SCLX CPIX vs SBFM

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Sunshine Biopharma Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sunshine Biopharma Inc.